Abstract
Objectives We performed a pooled analysis to evaluate the efficacy and adverse events (AEs) of olanzapine combined with dexamethasone plus compared with 5-HT3 RA plus dexamethasone for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in high and moderate emetogenic chemotherapy based on randomized controlled trials (RCTs).
Methods PubMed, EMBASE, Web of Science, the Cochrane Library, China Biomedical Literature database (CBM), WanFang Database, China National Knowledge Infrastructure (CNKI), and Chinese Science and Technology Periodical Database (VIP) (from their inception to April 2019) were searched to capture relevant articles. Relative risk (RR) with 95% confidence intervals (CIs) for CINV and AEs were all extracted or calculated.
Result Eleven studies with 1107 cancer patients were involved in this review. The pooled RR of delayed CINV (RR=0.50, 95%CI: 0.38-0.66, P<0.01) were significant decreased in olanzapine group. Besides, the occurrence of insomnia was statistically decreased. The rate of acute CINV (RR=0.60, 95%CI: 0.48–0.75, P<0.01) was also significant decreased. However only the percent of CINV □ and CINV □ were significant deceased in acute and delayed phase. Subgroup analysis demonstrated that the efficacy was no statistically significant difference between 5mg and 10mg for olanzapine.
Conclusion Olanzapine significant decreased the occurrence of CINV □ and □ and insomnia in high and moderately emetogenic chemotherapy. Compared with 10mg per day, 5mg oral may be more appropriate for patients with cancer.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Natural Science Foundation of China (Grant No.81360351, 81660512).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
All data of our review were extracted from the articles which published on journal.
